首页> 美国卫生研究院文献>Reumatologia >Assessment of anti-HBs antibody concentration in children with juvenile idiopathic arthritis treated with biological drugs vaccinated against viral type B hepatitis in infancy
【2h】

Assessment of anti-HBs antibody concentration in children with juvenile idiopathic arthritis treated with biological drugs vaccinated against viral type B hepatitis in infancy

机译:用婴儿乙型病毒性乙型肝炎疫苗接种生物药物治疗的儿童特发性关节炎儿童的抗HBs抗体浓度评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The introduction of vaccinations against viral hepatitis B in the years 1994–1996 in Poland significantly improved the epidemiological situation of hepatitis B virus (HBV) infections in our country. According to the report of the National Institute of Public Health – National Institute of Hygiene in 2018, 40 cases of acute hepatitis B were noted while still in the 1980s between 10 and 20 thousand new cases were reported annually. The aim of the study was to determine whether in children treated with biological drugs (adalimumab, etanercept, infliximab) due to juvenile idiopathic arthritis (JIA), vaccinated against hepatitis B in infancy, a protective concentration of anti-HBs antibodies persists. In patients, the value ≥ 10 mIU/ml is regarded as a protective concentration of antibodies, determined at least four weeks after administration of the last vaccine dose. Among healthy individuals, presence of anti-HBs antibodies in any concentration means seroprotection. No booster vaccinations are recommended in basically vaccinated healthy individuals.
机译:1994年至1996年,波兰采用了针对乙型病毒性肝炎的疫苗,这大大改善了我国乙型肝炎病毒(HBV)感染的流行病学状况。根据国家公共卫生研究所-国立卫生研究院的报告,2018年发现了40例急性乙型肝炎,而在1980年代,每年仍报告1万至2万例新病例。该研究的目的是确定在因幼年特发性乙型肝炎(JIA)接种幼年特发性关节炎(JIA)而因生物药物(阿达木单抗,依那西普,英夫利昔单抗)治疗的儿童中,抗-HBs抗体的保护浓度是否持续。在患者中,≥10 mIU / ml的值被视为抗体的保护性浓度,在给予最后一剂疫苗至少四周后确定。在健康个体中,任何浓度的抗HBs抗体的存在都意味着血清保护。在基本接种过疫苗的健康个体中,不建议加强接种。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号